Spruce Biosciences Q2 EPS $(0.22) Beats $(0.30) Estimate, Sales $1.61M Beat $1.50M Estimate
Portfolio Pulse from Benzinga Newsdesk
Spruce Biosciences (NASDAQ:SPRB) reported Q2 EPS of $(0.22), beating the $(0.30) estimate, and sales of $1.61M, beating the $1.50M estimate. EPS improved by 31.25% YoY, while sales decreased by 25.64% YoY.
August 12, 2024 | 8:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Spruce Biosciences reported better-than-expected Q2 EPS and sales, with EPS improving significantly YoY. However, sales decreased compared to the same period last year.
The better-than-expected EPS and sales figures are likely to have a positive short-term impact on SPRB's stock price. The significant improvement in EPS is a strong positive signal, although the YoY sales decline may temper some of the enthusiasm.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100